You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,790,674


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,790,674
Title:Methods of treatment using specific binding agents of human angiopoietin-2
Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
Inventor(s): Oliner; Jonathan Daniel (Newbury Park, CA), Min; Hosung (Newbury Park, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:11/499,892
Patent Claims:1. A method for treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a peptide or peptibody capable of binding Ang-2, wherein said peptide or peptibody comprises the amino acid sequence: TABLE-US-00057 WDPWT (SEQ ID NO: 65)

wherein said peptide is from about 5 to about 50 amino acids in length, and physiologically acceptable salts thereof.

2. The method according to claim 1 wherein the peptide or peptibody comprises the amino acid sequence: TABLE-US-00058 WDPWTC (SEQ ID NO: 66)

and physiologically acceptable salts thereof.

3. The method according to claim 2 wherein the peptide or peptibody comprises the amino acid sequence: TABLE-US-00059 Cz.sup.2WDPWT (SEQ ID NO: 67)

wherein z.sup.2 is an acidic or neutral polar amino acid residue, and physiologically acceptable salts thereof.

4. The method according to claim 3 wherein the peptide or peptibody comprises the amino acid sequence: TABLE-US-00060 Cz.sup.2WDPWTC (SEQ ID NO: 68)

wherein z.sup.2 is an acidic or neutral polar amino acid residue, and physiologically acceptable salts thereof.

5. The method according to claim 4 wherein the peptide or peptibody comprises the amino acid sequence: TABLE-US-00061 a.sup.1a.sup.2a.sup.3Ca.sup.5WDPWTCa.sup.12a.sup.13a.sup.14 (SEQ ID NO: 69)

wherein: a.sup.1, a.sup.2, and a.sup.3 are each independently amino acid residues; a.sup.5 is an amino acid residue; a.sup.12 is absent or an amino acid residue; a.sup.13 is absent or a neutral hydrophobic, or neutral polar, or a basic amino acid residue; a.sup.14 is a neutral hydrophobic or neutral polar amino acid residue; and physiologically acceptable salts thereof.

6. The method according to claim 5 wherein: a.sup.1 is V, I, P, W, G, S, Q, N, E, K, R, or H; a.sup.2 is V, P, M, G, S, Q, D, E, K, R, or H; a.sup.3 is A, V, P, M, F, T, G, D, E, K, or H; a.sup.5 is A, V, G, Q, N, D, or E; a.sup.12 is S, Q, N, D, E, K, or R; a.sup.13 is L, T, or H; a.sup.14 is V, L, I, W, or M; and physiologically acceptable salts thereof.

7. The method according to claim 6 wherein: a.sup.1 is Q; a.sup.2 is E; a.sup.3 is E; a.sup.5 is D, or E; a.sup.12 is D or E; a.sup.13 is H; and a.sup.14 is M; and physiologically acceptable salts thereof.

8. The method according to claim 1 wherein the peptide or peptibody comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 4, and SEQ ID NO: 76 to SEQ ID NO: 118, inclusive, and physiologically acceptable salts thereof.

9. The method according to claims 1-4 further comprising administering at least one anti-inflammatory agent.

10. The method according to claim 9 wherein the anti-inflammatory agent comprises at least one of a disease modifying anti-rheumatic drug (DMARD), slow acting anti-rheumatic drug (SAARD), and non-steroidal anti-rheumatic drug (NSAID).

11. The method according to claim 9 wherein the anti-inflammatory agent comprises at least one of methotrexate, a TNF inhibitor, a IL-1 inhibitor, a TACE inhibitor, a COX-2 inhibitor, and a P-38 inhibitor.

12. The method according to claim 11 wherein the TNF inhibitor comprises at least one of etanercept, adalimumab, pegsunercept sTNF-R1, onercept, and infliximab.

13. The method according to claim 11 wherein said IL-1 inhibitor is at least one of anakinra, IL-1 TRAP, IL-1 antibody, and soluble IL-1 receptor.

14. The method according to claim 9 wherein the administration is concurrent administration.

15. The method according to claim 9 wherein the administration is non-concurrent administration.

Details for Patent 7,790,674

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL MINI etanercept Injection 103795 09/14/2017 ⤷  Try a Trial 2021-10-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.